Project Grant R21MH136643

Award Date 6/5/24
Completion Date 4/30/26
Dollars Obligated $680K
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
Providence, RI 02903, USA
Similar Awards
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), will support research to investigate the molecular mechanisms underlying sex-specific behavioral deficits in mouse models of autism spectrum disorder (ASD) and other neurodevelopmental disorders. The $431,750 award, spanning from May 1, 2025 to April 30, 2027, will be used by Rutgers, The State University of New Jersey to: 1) Determine whether gonadal...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), is funding research to investigate sex-dependent dysregulation of parvalbumin interneurons as a potential pathway to Autism Spectrum Disorder (ASD). The $251,250 award to the Feinstein Institutes for Medical Research will support a study examining the impact of in utero exposure to anti-CASPR2 antibodies on the development and function of parvalbumin...
This $3.5 million project grant from the National Institutes of Health's National Institute on Aging will fund research into sex differences related to epigenetic parent-of-origin effects and Alzheimer's disease. The Regents of the University of California, San Francisco will investigate how the maternal versus paternal X chromosome impacts neural vulnerability to Alzheimer's-related deficits in mouse models and primary neurons. The researchers hypothesize that imprinting or silencing of genes...
This Project Grant award of $756,565.44 from the National Institutes of Health (NIH) National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) supports functional analysis research on histone modifier genes associated with autism spectrum disorders (ASD) in vertebrate development. The primary awardee is the University of California, Los Angeles (UCLA), which will leverage its extensive research capabilities, facilities, and...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $388,800 to The Trustees of Columbia University in the City of New York to conduct research on the relationship between genetic variants associated with both autism spectrum disorder (ASD) and schizophrenia (SCZ), and their impact on cognitive function and psychopathology in individuals with ASD. The study will remotely assess cognition and...
This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), supports research to elucidate the cellular and molecular mechanisms underlying autism spectrum disorder (ASD) pathology associated with Chromodomain Helicase DNA-Binding Protein 8 (CHD8) haploinsufficiency. The $164,992 award to the University of California, Davis, with a project period from...
This $443,121 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports the University of California, Santa Cruz in conducting innovative research to understand dysregulated protein synthesis, or translation, in an autism spectrum disorder (ASD) model. The project aims to leverage cutting-edge cryo-electron microscopy (cryo-EM)...
The National Institute of Mental Health (NIMH) awarded a $1,111,187 Project Grant (CFDA 93.242 Mental Health Research Grants) to Georgetown University to investigate how a gene called CHD1, which is linked to autism spectrum disorder (ASD), impacts synaptic homeostatic plasticity - the mechanisms that stabilize synaptic function. The 5-year research project, which began in July 2024, will employ a multifaceted approach including genetics, electrophysiology, imaging, transcriptomics, and...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $194,375 to the University of Wisconsin - Madison to characterize the role of midbody remnants in influencing cell fate decisions in autism spectrum disorder (ASD). The primary objectives are to: 1) Determine how an ASD-associated PTEN mutation alters the molecular composition of midbody remnants, and 2) Examine how midbody remnant uptake...
This federal Project Grant award of $1,416,226 was provided by the National Institute on Deafness and Other Communication Disorders (NIDCD) under the Research Related to Deafness and Communication Disorders program (CFDA 93.173). The grant supports research to characterize the pragmatic language profiles of females with Autism Spectrum Disorder (ASD) and their unaffected relatives, referred to as the Broad Autism Phenotype (BAP). The 5-year project aims to apply advanced phenotyping methods to...

UNCOVERING SEX-SPECIFIC DIFFERENCES IN ASH1L-DISEASE - PROJECT SUMMARY AUTISM SPECTRUM DISORDER (ASD) AFFECTS 1 IN 36 PEOPLE AND IS A HIGHLY HETEROGENEOUS CONDITION THAT HAS LIMITED THERAPEUTIC INTERVENTIONS AND AFFECTS MALES MORE OFTEN THAN FEMALES. SIMILARLY OTHER DISORDERS LIKE ATTENTION DEFICIT HYPERACTIVE (ADHD), TOURETTE SYNDROME (TS) AND SCHIZOPHRENIA (SCZ) HAVE SEX-SPECIFIC DIFFERENCES IN THEIR PREVALENCE AND CLINICAL PRESENTATION. HOWEVER, THE PRECISE CELLULAR AND MOLECULAR MECHANISMS THAT UNDERLIE SEX-SPECIFIC DIMORPHISMS ASSOCIATED THESE NEUROPSYCHIATRIC DISORDERS ARE UNDERSTUDIED. OUR LONG- TERM GOAL IS TO DEFINE THE MECHANISMS THAT UNDERLIE SEX-SPECIFIC DIFFERENCES RELATED TO NEUROPSYCHIATRIC DISORDERS. HUMAN GENETICS STUDIES HAVE IDENTIFIED HIGH RISK VARIANTS IN GENES THAT ENCODE CHROMATIN REGULATORY FACTORS ASSOCIATED WITH ASD, TS, ADHD, AND SCZ. OUR STUDIES FOCUS ON THE HISTONE METHYLTRANSFERASE ASH1L WHICH HAS BEEN IDENTIFIED AS A GENE OF HIGH IMPORTANCE THAT RAISES ABOVE GENOME WIDE SIGNIFICANCE IN LARGE SEQUENCING STUDIES OF ASD, TS AND SCZ. WE FIND THAT BOYS WITH MUTATIONS IN ASH1L PRESENT MORE OFTEN WITH ASD AND ADHD, WHILE GIRLS WITH ASH1L MUTATIONS ARE MORE LIKELY TO PRESENT SEIZURES. HOWEVER, THE MOLECULAR MECHANISMS UNDERLYING SEX-SPECIFIC DIFFERENCES ASSOCIATED WITH DEFICITS IN ASH1L ARE UNKNOWN. WE DEVELOPED A HIGH-RISK, HIGH-REWARD RESEARCH PROGRAM THAT BRINGS TOGETHER IN-DEPTH CLINICAL NEURO-PHENOTYPING AND STEM CELL PRE-CLINICAL STUDIES TO UNCOVER MECHANISMS UNDERLYING SEX-SPECIFIC DIFFERENCES ASSOCIATED WITH MUTATIONS IN ASH1L. OUR CENTRAL HYPOTHESIS IS THAT ASH1L MODULATES TRANSCRIPTIONAL PROGRAMS THAT GOVERN NEURONAL STRUCTURE AND FUNCTION, AND THAT SEX-SPECIFIC POST-TRANSLATIONAL HISTONE MODIFICATIONS LEAD TO GENOME- WIDE ALTERATION OF MOLECULAR PROGRAMS THAT UNDERLIE MALE AND FEMALE PHENOTYPIC DIFFERENCES IN ASH1L RELATED DISORDERS. WE WILL TEST THIS HYPOTHESIS IN THE FOLLOWING SPECIFIC AIMS: AIM-1 WILL DEFINE THE PHENOTYPIC DIVERSITY AND SEVERITY OF NEUROLOGICAL PRESENTATIONS ASSOCIATED WITH ASH1L DISEASE WITH RESPECT TO SEX-SPECIFIC DIFFERENCES. AIM 2 WILL DEFINE SEX-SPECIFIC CELLULAR AND MOLECULAR PHENOTYPES CAUSED BY ASH1L DYSREGULATION IN HUMAN NEURONS DERIVED FROM MALE AND FEMALE INDIVIDUALS WITH ASH1L MUTATIONS. THE IMPACT OF OUR WORK IS THAT DEFINING THE CLINICAL DIVERSITY AND SEVERITY OF ASH1L NEUROLOGICAL PHENOTYPES IN A MALE AND FEMALE SPECIFIC MANNER WILL BE IMPORTANT FOR PATIENTS, FAMILIES, AND THEIR PHYSICIANS WITH RESPECT TO MEDICAL TREATMENT. OUR WORK WITH PATIENTS, WILL ALLOW US TO UNCOVER SEX-SPECIFIC DIFFERENCES CLINICALLY AND MECHANISTICALLY USING PATIENT IPSC-DERIVED NEURONS, WHICH WILL ALLOW US TO IDENTIFY TARGETS FOR THERAPEUTIC INTERVENTIONS. FINALLY, OUR WORK WILL ALSO ALLOW US TO BEGIN TO PREPARE THE ASH1L PATIENT COMMUNITY FOR LARGER SCALE CLINICAL STUDIES.

Posted 6/5/24, 12:00 AM